US 12,461,101 B2
Blood-based signatures for diagnosis and sub-typing of inflammatory bowel disease subsets
Samuel J. Rubin, Stanford, CA (US); and Aida Habtezion, Stanford, CA (US)
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Appl. No. 17/296,941
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Dec. 20, 2019, PCT No. PCT/US2019/067989
§ 371(c)(1), (2) Date May 25, 2021,
PCT Pub. No. WO2020/142276, PCT Pub. Date Jul. 9, 2020.
Claims priority of provisional application 62/787,977, filed on Jan. 3, 2019.
Prior Publication US 2021/0396753 A1, Dec. 23, 2021
Int. Cl. G01N 33/569 (2006.01); C12Q 1/6883 (2018.01); G01N 1/30 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/56972 (2013.01) [C12Q 1/6883 (2013.01); G01N 1/30 (2013.01); G01N 33/6893 (2013.01); G01N 2001/302 (2013.01); G01N 2800/065 (2013.01)] 20 Claims
 
1. A method of treatment, comprising:
(a) labeling peripheral blood leukocytes isolated from a patient that has or is suspected of having inflammatory bowel disease (IBD) with a panel of fewer than 20 antibodies, wherein the antibodies bind to CD123, HLA-DR, CD11c, CD19, CD20, CCR9, GPR15 and CD56, and, optionally, IgD and CD27, and wherein the antibodies are each conjugated to a label and the labels conjugated to the antibodies distinguish the antibodies from one another;
(b) analyzing binding of the antibodies to the peripheral blood leukocytes;
(c) identifying the patient as having Crohn's disease or ulcerative colitis based on the analysis of (b), wherein the identifying comprises:
(i) gating immune cells based on the expression of CD123, HLA-DR, CD11c, CD19, CD20, CCR9, GPR15 and CD56, and, optionally, IgD and CD27;
(ii) inputting the results of (i) into a probability model; and
(iii) determining a probability of the patient having Crohn's disease or ulcerative colitis based on the results of (ii); and
(d) treating the patient with surgery of the intestine and/or an immunosuppressive agent.